Irene Becklund Sells 4,490 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 4,490 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $141,435.00. Following the completion of the sale, the insider owned 6,790 shares in the company, valued at approximately $213,885. This represents a 39.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Irene Becklund also recently made the following trade(s):

• On Tuesday, June 16th, Irene Becklund sold 7,573 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.25, for a total value of $229,083.25.

Hims & Hers Health Stock Up 1.6%

Hims & Hers Health stock traded up $0.50 during midday trading on Wednesday, reaching $31.97. The company’s stock had a trading volume of 23,080,110 shares, compared to its average volume of 30,466,682. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The company has a market cap of $7.40 billion, a P/E ratio of -355.22, a P/E/G ratio of 56.60 and a beta of 2.37. The business has a 50-day simple moving average of $25.87 and a 200-day simple moving average of $26.65.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. During the same quarter in the prior year, the business earned $0.20 earnings per share. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares during the period. Capital World Investors boosted its stake in shares of Hims & Hers Health by 1.2% during the third quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after buying an additional 223,892 shares during the period. Farallon Capital Management LLC boosted its stake in shares of Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares during the period. State Street Corp boosted its stake in shares of Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after buying an additional 132,311 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after buying an additional 608,950 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on HIMS. Leerink Partners raised their price target on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research note on Monday, March 16th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 5th. Evercore set a $24.00 target price on shares of Hims & Hers Health in a report on Tuesday, February 24th. Truist Financial increased their price target on shares of Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, May 22nd. Finally, BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $29.37.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Barclays sees breakout potential for Hims & Hers as the Novo partnership and weight-loss offerings could drive stronger revenue and EBITDA growth in the second half of 2026. HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership
• Positive Sentiment: Analysts are focused on an upcoming FDA peptide review that could serve as the next major growth catalyst for Hims & Hers. HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
• Positive Sentiment: Investor enthusiasm remains high around peptides and GLP-1 treatments, with some bullish commentary suggesting the market opportunity could be larger than current forecasts. Hims & Hers Stands to Get a Big Chunk of the $2.2B Peptides Market
• Neutral Sentiment: Insider selling disclosures from COO Michael Chi and employee Irene Becklund were made under pre-arranged 10b5-1 plans and were tied to tax withholding from equity vesting, which makes them less concerning than open-market insider selling.
• Neutral Sentiment: Market commentary highlighted Hims & Hers’ strong recent share performance and ongoing momentum, but did not add a new fundamental catalyst. Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
• Negative Sentiment: The insider sales, while routine, may still create some short-term caution for investors if the stock’s valuation remains stretched.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.